Floatz logo

(1R,3S,4R)-4-((3AR,9BR)-9B-((4-FLUOROPHENYL)SULFONYL)-7-(PERFLUOROPROPAN-2-YL)-2,3,3A,4,5,9B-HEXAHYDRO-1H-BENZO(E)INDOLE-3-CARBONYL)-3-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID

Rheumatoid Arthritis

Bristol-Myers SquibbSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Rheumatoid Arthritis cohort.

Asset / SponsorPhaseRating
Naltrexone
Truway Health, Inc.
Phase 4BBB
METHOTREXATE
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3BB
IBUPROFEN
Amgen
Phase 3BB
Tocilizumab
Hoffmann-La Roche
Phase 3BB
Buprenorphine
Mundipharma Pte Ltd.
Phase 4BB

View all 38 →

Same molecule, other indications

(1R,3S,4R)-4-((3AR,9BR)-9B-((4-FLUOROPHENYL)SULFONYL)-7-(PERFLUOROPROPAN-2-YL)-2,3,3A,4,5,9B-HEXAHYDRO-1H-BENZO(E)INDOLE-3-CARBONYL)-3-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID is also rated in:

ankylosing spondylitisDormant
CCC
Indicative ·
48 / 100
View asset →
inflammatory bowel diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
psoriasisDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →